Subscribe to the RNA-Seq Blog
Featured Events
.png)
Media Partners
Polls
Loading ...
Dec
29
RNA-Seq to deliver a quantum leap forward in understanding Alzheimer’s disease
Filed Under Publications
The prevalence of Alzheimer’s disease (AD) is increasing rapidly in the Western world and is poised to have a significant economic and societal impact. Current treatments do not alter the underlying disease processes meaning new treatments are required if this imminent epidemic is to be averted. The clinical manifestations of AD are secondary to a substantial loss of cortical neurons.
Effective neuroprotective strategies will require the discovery of both preclinical markers to identify susceptible patients and the early pathogenic mechanisms to serve as therapeutic targets. While the biomarkers and pathogenic mechanisms may overlap, it is likely that new approaches are required to identify novel elements of the disease.
Transcriptomic analyses, that assume no a priori etiological hypotheses, promise much in elucidating the pathogenesis of complex diseases like AD. RNA-Seq is not only highly suited to investigations of the genomically complex human brain tissue but it can potentially overcome technical issues inherent to case-control comparisons of postmortem brain tissue in neurodegenerative diseases. Moreover, RNA-Seq goes beyond the detection of transcripts that correspond to an existing genomic sequence. With this technique, the exact location of transcription boundaries can be identified with single base resolution. These features make RNA-Seq particularly useful for studying complex transcriptomes, such as those found in the human brain.
Sutherland GT, Janitz M, Kril JJ. (2010) RNA-Seq and the pathogenesis of Alzheimer’s disease. Journal of Neurochemistry [Epub ahead of print]. [article]
Incoming search terms:
- rna seq and dementia
Comments
One Response to “RNA-Seq to deliver a quantum leap forward in understanding Alzheimer’s disease”
Leave a Reply
Social Networking Pages
-
SEQanswers – RNA Sequencing- Problem with cummeRbund diffData() May 20, 2013Hi all, I'm running Tophat/cufflinks/cuffdiff for differential gene expression and analysis with cummeRbund (v 2.0.0). I'm having an issue with... […]Enrique Zudaire
- How to increase rowsize in heatmap? May 16, 2013Hi, I am a complete newbie to all things cummeRbund and am currently fighting with generating readable heatmaps. When I use ... […]Mags
- novoalign mapping May 15, 2013Hi, I want to use novoalign to map reads - allowing up to 15 mismatches for 100 bp paired-end reads I am new to novoalign(went through the... […]abh
- Design of expt across multiple lanes May 15, 2013Hi, I am performing an RNA-seq experiment to look at differential expression. The design is as follows: 2 populations x 3 biological... […]jbono
- RNA kinds expected in RNA-seq results May 15, 2013Hi, We use RNA isolation and library preparation protocols which capture polyadenylated RNA. My question is what kinds of RNA can we expect to... […]Kocur
- Discrepancy between genotype and expressed alleles May 15, 2013Hi all, I am working on the analysis of allele-specific expression using both genotype information and RNA-seq data from the same individuals. I... […]RedMary
- Problem with cummeRbund diffData() May 20, 2013
- Biostar – RNA-Seq
- How do TopHat options -g , --supress-hits, and Bowtie options interplay?Hi, I am currently using TopHat2 to map RNA-seq runs. I think there have been some changes pertaining the -g option. Does anyone know how it works now? I used to think that setting -g would look for n alignments for a given read, report them [if top-scoring] and discard those reads that had more than g [top scoring] alignments. Now, the description sounds mo […]
- What happened to -k in TopHat for multiple-mapping reads?Selecting -g n in tophat does not discard reads mapping more than n, but instead only reports n alignments for those out all all their TOP scoring alignments. I think there used to be an option -k that would allow one to discard reads that topped x alignments -- whatever happened to that? I only see -g in the tophat 2 manual, no reporting options like before […]
- Does tophat use the library-type information for mapping, or just for the XS flag?When I specify library-type to TopHat, i.e., first-strand, second-strand, unstranded, TopHat appends a value + or - to the XS:A tag, which is useful for subsequent analyses, such as annotation. However, does this information influence the "mappability" of reads, or is this unaffected? My guess is that the information will be considered for mapping […]
- Purpose of Y-shaped adapters in Illumina Sequencing?Hi all, Y adapters different sequences to be annealed to the 5' and 3' ends of each molecule in a library. The arms of the Y are unique, and the middle part, connected to the DNA fragment, is complementary. What are the advantages of this? My take of this over having fully-complementary adapters (ADAPTER1 - - - - - ADAPTER1) is that: -Upon primer a […]
- Cell Type composition in a tissue based on gene marker expressionI am not sure if the following would even make sense.... Tissues are composed of composite cell types, and often there are studies such as microarray/NGS where we perform a collective sampling of cells from these tissues. Information about the composition (say percentage of cell type) is not taken into consideration. In some case (such as brain/cancer), ther […]
- Which SNP caller / method to use after aligning RNA-seq with TopHatWhich SNP caller / method can / should I use after aligning RNA-seq data with TopHat? For genomic data I use GATK, but supposedly it is not just as easy as running GATK on the TopHat RNA-seq data. The team from Broad has no information / documentation on how to use GATK for RNA-seq data. I don't have any variants yet from DNA re-sequencing. […]
- How do TopHat options -g , --supress-hits, and Bowtie options interplay?
The experience of alzheimer’s disease differ from oneanother so caregiving approach will be different to each patient. How to take care of yourself both physically and emotionally as you’re caring for someone with Alzheimer’s disease or dementia.